Early detection of corneal eye diseases and conditions can help prevent permanent damage.
Some corneal conditions are:
Keratitis.
Keratitis is an inflammation (redness and swelling) of the cornea.
Corneal dystrophies.
Corneal dystrophies cause cloudy vision when material builds up on the cornea.
Keratoconus.
Keratoconus is a broad term used by ophthalmologists and optometrists to cover conditions associated with changes in corneal shape into a cone-like shape, can cause abnormal posterior ectasia, corneal thickness distribution, clinical non-inflammatory corneal thinning, it can also cause myopia and irregular astigmatism, this Affects quality of life and is a burden on patients and their families.
Current treatments for Cornea disease include corneal transplantation and the revolutionary Descemet’s Membrane Endothelial Keratoplasty (DMEK), an ultra-thin partial thickness corneal transplant for the treatment of Fuchs’ Dystrophy and other corneal diseases that target the diseased layers of the cornea and preserve as much of the healthy cornea as possible. also Deep Anterior Lamellar Keratoplasty (DALK), full thickness corneal transplants, and keratoprostheses.
Dr. Villavicencio and Catalina Eyecare are excited to offer the FDA-approved treatment of keratoconus using Corneal Collagen Cross-Linking, which can slow or even stop the progression of keratoconus. Avedro, Inc., an ophthalmic pharmaceutical and medical device company, has recently received approval from the U.S. Food and Drug Administration (FDA) for Photrexa Viscous, Photrexa and the KXL Collagen Cross-Linking System. Dr. Villavicencio is proud to have been part of a nationwide team involved in the Avedro study, which resulted in the FDA approval of this new device and treatment. Dr. Villavicencio has been performing Collagen Cross-Linking since 2014, as part of the KXL Study in Indianapolis, IN. Since late 2016, Dr. Villavicencio has been offering this technology to the Tucson and Southern Arizona area.
